Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share price, results

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Standalone, Rs crore

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	58	47	43	61	75	74	59	76	74	73	64	82
Expenses	49	44	41	51	58	58	50	61	58	57	53	65
Operating Profit	8	3	3	10	16	16	9	14	16	16	11	17
OPM %	14%	7%	6%	17%	22%	21%	15%	19%	22%	22%	17%	21%
Other Income	2	3	2	-2	2	26	3	3	3	1	3	3
Interest	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	1	2	2	2	2	2	2	2	2
Profit before tax	10	5	5	7	15	39	9	14	17	15	12	18
Tax %	25%	25%	22%	25%	25%	17%	24%	25%	25%	25%	25%	25%
Net Profit	7	4	4	5	11	32	7	11	13	11	9	13
EPS in Rs	1.14	0.60	0.54	0.81	1.73	4.82	0.99	1.62	1.89	1.64	1.31	2.00

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	143	144	127	167	159	188	218	237	209	269	287	294
Expenses	132	138	138	157	150	169	192	203	186	218	229	233
Operating Profit	12	6	-11	9	9	19	26	34	23	51	58	61
OPM %	8%	4.0%	-9%	6%	5%	10%	12%	14%	11%	19%	20%	21%
Other Income	1	13	0	1	3	4	3	2	9	28	10	10
Interest	5	3	1	1	1	1	0	0	1	1	1	1
Depreciation	3	2	0	1	1	1	2	1	2	8	9	9
Profit before tax	4	14	-12	9	9	22	27	35	30	70	58	61
Tax %	20%	18%	-1%	20%	16%	22%	29%	23%	25%	21%	25%
Net Profit	3	12	-12	7	8	17	19	27	22	55	43	45
EPS in Rs	0.50	1.81	-1.76	1.10	1.20	2.60	2.88	4.08	3.40	8.34	6.43	6.84
Dividend Payout %	8%	2%	-2%	9%	17%	15%	56%	49%	59%	30%	62%

	10 Years	5 Years	3 Years	TTM	1 Year	Last Year
Compounded Sales Growth	7%	9%	7%	4%
Compounded Profit Growth	30%	21%	16%	10%
Stock Price CAGR	31%	30%	12%		7%
Return on Equity	11%	16%	15%			17%

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	13	13	13	13	13	13	13	13	13	13	13	13
Reserves	82	85	97	85	91	98	109	120	146	174	227	263
Borrowings	39	38	8	8	4	5	7	0	6	9	9	8
Other Liabilities	19	22	25	23	28	31	35	31	30	21	29	32
Total Liabilities	154	159	143	130	136	147	164	164	195	217	278	317
Fixed Assets	52	52	22	21	22	22	26	23	24	9	94	85
CWIP	0	0	0	3	4	4	0	0	0	0	0	0
Investments	0	0	0	0	0	11	15	51	1	0	0	0
Other Assets	102	108	121	105	110	109	123	91	170	208	184	231
Total Assets	154	159	143	130	136	147	164	164	195	217	278	317

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	4	9	-3	-2	31	11	28	7	47	35	55	47
Cash from Investing Activity	-0	-2	41	-3	-1	-11	-2	-26	-58	-25	-45	-36
Cash from Financing Activity	-1	-6	-34	-1	-6	-1	-7	-18	-0	-9	-12	-12
Net Cash Flow	2	1	5	-6	24	-0	19	-36	-11	2	-2	-1
Free Cash Flow	4	6	40	-5	30	12	28	6	48	35	90	47
CFO/OP	53%	83%	-6%	14%	311%	150%	164%	54%	158%	189%	124%	101%

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	119	106	100	73	45	49	25	26	32	19	18	22
Inventory Days	176	246	295	307	164	191	134	122	82	68	58	51
Days Payable	42	60	56	54	59	76	82	76	66	35	37	40
Cash Conversion Cycle	252	292	339	325	150	164	77	72	48	53	39	33
Working Capital Days	68	72	154	149	67	55	32	59	34	52	9	11
ROCE %	5%	7%	3%	-10%	9%	9%	18%	20%	25%	17%	23%	23%

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	68.72%	68.48%	68.09%	68.04%	67.98%	67.82%	67.77%	67.65%	67.54%	67.39%	67.89%	69.06%
FIIs	0.38%	0.53%	0.73%	1.10%	2.30%	2.10%	2.10%	2.17%	2.12%	2.12%	2.44%	2.30%
DIIs	0.82%	0.82%	0.84%	0.84%	0.11%	0.00%	0.00%	0.05%	0.08%	0.15%	0.22%	0.62%
Public	30.07%	30.16%	30.33%	30.01%	29.63%	30.10%	30.11%	30.12%	30.25%	30.34%	29.44%	28.04%
No. of Shareholders	16,041	15,785	16,282	15,748	15,633	18,471	21,085	22,899	24,653	24,895	26,264	24,181

Fundamentals

Market Cap₹ 1,552 Cr.

Current Price₹ 235

Stock P/E33.0

Book Value₹ 41.2

ROCE22.7 %

ROE17.3 %

Dividend Yield1.70 %

Face Value₹ 2.00

Compounded Sales Growth (TTM)4%

Compounded Profit Growth (TTM)10%

Standalone figures.

Valuation

Market capRs 1,552 Cr

Enterprise valueRs 1,454 Cr

P/E (TTM)34.13x

Price to book5.62x

Price to sales5.28x

EV / EBITDA20.46x

EV / EBIT23.52x

EV / sales4.95x

Price to cash flow33.15x

Earnings yield2.93%

Dividend yield1.73%

P/E, 3-year average22.56x

P/B, 3-year average4.01x

P/E, 5-year average19.29x

P/B, 5-year average3.28x

Profitability

Operating margin (excl. other income)20.22%

Operating margin (incl. other income)23.67%

EBITDA margin24.18%

Pre-tax margin20.68%

Net profit margin15.47%

Net margin, latest quarter16.04%

ROE16.69%

ROCE21.95%

ROA14.48%

ROE, 3-year average18.52%

ROCE, 3-year average23.58%

ROA, 3-year average15.91%

ROE, 5-year average17.74%

ROCE, 5-year average23.00%

ROA, 5-year average14.82%

ROIC (approx.)25.97%

Tax rate25.10%

Other income / net worth3.59%

Growth

Sales growth (latest year)6.89%

Profit growth (latest year)-22.18%

Sales CAGR, 3 years6.66%

Sales CAGR, 5 years8.85%

Profit CAGR, 3 years17.26%

Profit CAGR, 5 years20.35%

Sales growth QoQ28.08%

Profit growth QoQ50.57%

Sales growth YoY (latest quarter)8.76%

Profit growth YoY (latest quarter)22.13%

Per share

EPS (TTM)Rs 6.79

EPS (latest year)Rs 6.43

EPS (latest quarter)Rs 1.97

EPS, 3-year averageRs 7.76

EPS, 5-year averageRs 8.13

Book value per shareRs 41.24

Sales per shareRs 43.88

Cash flow per shareRs 6.99

Free cash flow per shareRs 7.02

Dividend per share (latest year)Rs 4.00

Dividend per share, 3-year averageRs 3.83

Dividend per share, 5-year averageRs 4.10

Dividends

Dividend payout62.16%

Dividend payout, 3-year average50.34%

Dividend payout, 5-year average51.12%

Efficiency

Asset turnover0.91x

Fixed asset turnover3.37x

Inventory turnover7.24x

Inventory days50 days

Debtor days22 days

Debtors turnover16.71x

Creditor days40 days

Cash conversion cycle33 days

Working capital days11 days

Leverage

Total debtRs 8 Cr

Cash and bankRs 106 Cr

Net debtRs -98 Cr

Debt to equity0.03x

Net debt / EBITDA-1.38x

Interest coverage60.00x

Current ratio (filing 2026-03-31)5.06x

Quick ratio (filing 2026-03-31)4.54x

Trade payables (filing 2026-03-31)Rs 12 Cr

Owners' fund to total sources87.21%

Debt to assets2.58%

Cash flow

Cash from Operating Activity (latest year)Rs 47 Cr

Cash from Investing Activity (latest year)Rs -36 Cr

Cash from Financing Activity (latest year)Rs -12 Cr

Net Cash Flow (latest year)Rs -1 Cr

Free cash flow (latest year)Rs 47 Cr

FCFE (approx.: FCF + change in debt)Rs 46 Cr

Cash from ops / profit, 5 years1.15x

Sales to cash flow6.14x

Statement figures

Net sales (TTM)Rs 294 Cr

Net sales (latest year)Rs 287 Cr

Sales (latest quarter)Rs 82 Cr

Operating profit excl. other income (latest year)Rs 58 Cr

Operating profit (latest quarter)Rs 17 Cr

Other income (TTM)Rs 10 Cr

EBITDA (TTM)Rs 71 Cr

PBDT (TTM)Rs 70 Cr

Profit before tax (TTM)Rs 61 Cr

Tax (latest year)Rs 14 Cr

Net profit (TTM)Rs 45 Cr

Net profit (latest year)Rs 43 Cr

Net profit (latest quarter)Rs 13 Cr

Depreciation (TTM)Rs 9 Cr

Depreciation (latest quarter)Rs 2 Cr

Interest (TTM)Rs 1 Cr

Cost of goods sold (latest year)Rs 106 Cr

Total expenditure (latest year)Rs 229 Cr

Total income (latest year)Rs 297 Cr

Share capitalRs 13 Cr

ReservesRs 263 Cr

Shareholders' fundsRs 276 Cr

Total assetsRs 317 Cr

Net blockRs 85 Cr

ReceivablesRs 17 Cr

InventoryRs 15 Cr

Other liabilitiesRs 32 Cr

Shares outstanding (crore)6.70

Ownership

Promoter holding69.06% (+1.41 in a year)

Computed by MarketFriction from the standalone statements. Returns use average balances.

P/E 34.1 is at the 59th percentile of its own 8.4-year range (median 28.1, low 6.0, high 90.8).

P/B 5.62 is at the 59th percentile (median 4.66).

Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.

Period	JAGSNPHARM	Nifty 50	Difference
1 week	-5.0%	-2.8%	-2.2 pts
1 month	-3.3%	-6.8%	+3.5 pts
3 months	-2.1%	-7.6%	+5.6 pts
6 months	+25.9%	+0.4%	+25.5 pts
1 year	-1.4%	-9.9%	+8.6 pts
2 years	+41.0%	-13.6%	+54.5 pts
3 years	+38.1%	+14.2%	+24.0 pts
5 years	+272.3%	+27.9%	+244.4 pts

1 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 0 sold (share counts, price move removed).

Fund	Weight	Est. Cr	3m shares
Bandhan BSE Healthcare Index Fund	0.03%	0	-1%

Red flags

F-score 6 of 8

look	Regulator order or action Regulator order or action 2025-12-30: Jagsonpal Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed

Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026

Sales ₹82 Cr +7.9% vs Jun 2025. Net profit ₹13 Cr +18.2%.

Against our estimate for Jun 2026: sales +4.2%, profit +11.8% in line. Our estimate for Sep 2026: sales Rs 80 Cr, profit Rs 12 Cr (how).

Activity

Compare

Company	Mcap (Cr)	P/E	ROCE
Sun Pharmaceutical Industries Ltd	447,476	35.4	20.5 %
Divis Laboratories Ltd	250,363	84.0	22.0 %
Torrent Pharmaceuticals Ltd	186,152	83.4	15.2 %
Zydus Lifesciences Ltd	119,750	24.6	21.1 %
Cipla Ltd	111,430	31.1	15.5 %
Laurus Labs Ltd	106,928	97.8	17.8 %
Mankind Pharma Ltd	105,120	49.3	13.5 %
Dr Reddys Laboratories Ltd	104,494	32.4	13.0 %
Aurobindo Pharma Ltd	97,682	25.8	12.9 %
Lupin Ltd	93,840	15.8	29.9 %
Glenmark Pharmaceuticals Ltd	68,905	22.1	39.8 %
Alkem Laboratories Ltd	62,772	27.6	21.2 %
Biocon Ltd	61,439	84.5	3.61 %
Abbott India Ltd	57,949	35.9	44.8 %
Gland Pharma Ltd	49,333	43.1	15.1 %

No bulk or block deals on record.

Ex-date	Action	Factor
2026-09-04	Dividend - Rs 4 Per Share
2026-05-04	Buy Back
2025-09-12	Dividend - Rs 2.50 Per Share
2025-01-08	Face Value Split (Sub-Division) - From Rs 5/- Per Share To Rs 2/- Per Share	0.4000
2024-09-06	Dividend - Rs 5 Per Share
2023-08-21	Dividend - Rs 5 Per Share
2022-06-08	Extra Ordinary General Meeting
2021-10-29	Interim Dividend - Rs 4 Per Share
2021-09-22	Annual General Meeting/Dividend - Re 1 Per Share
2020-09-22	Annual General Meeting/Dividend - Rs 0.50 Per Share
2019-09-20	Annual General Meeting/Dividend - Rs 0.25 Per Share
2018-09-18	Annual General Meeting/Dividend Re 0.10 Per Share
2017-09-21	Annual General Meeting/Dividend - Re 0.10 Per Share (Date Revised)
2016-09-21	Annual General Meeting/ Dividend - Re 0.10/- Per Share (Book Closure Start Date Revised)
2015-09-21	Annual General Meeting/ Dividend - Re 0.10/- Per Share
2014-09-25	Annual General Meeting / Dividend - Re 0.50/- Per Share
2013-09-25	Annual General Meeting/Dividend Re 0.50/- Per Share
2012-09-21	Annual General Meeting/Dividend Re 0.50 Per Share
2011-09-23	Annual General Meeting And Dividend Re.0.50 Per Share
2010-09-21	Annual General Meeting And Dividend Re.0.50 Per Share
2009-09-23	Agm/Div-Re.0.25 Per Share
2008-09-24	Agm/Div-Re.0.10 Per Share
2007-09-21	Agm/Div-Re.0.10 Per Sh
2006-09-26	Agm/Div-Re.0.10/- Per Sh

Date	Type	What it says
2026-10-01	Updates	Subsequent to fulfilment of the Conditions Precedent under the BTA the transaction has been consummated with effect from today i.e., October 01, 2026....
2026-09-30	Updates	Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022.
2026-09-23	Press Release	A press release dated September 23, 2026, titled "Press Release on Acquisition of the wellness portfolio of group Pharmaceuticals Limited.".
2026-09-23	General Updates	The Acquisition of Wellness Portfolio of Group Pharmaceuticals Limited.
2026-09-21	Shareholder meeting	Voting results.
2026-09-18	Shareholder meeting	Shareholders meeting
2026-08-27	Shareholder meeting	Notice of Annual General Meeting to be held on September 18, 2026
2026-08-27	Updates	Providing a web-link of the Annual Report 2025-26 to members.
2026-08-24	Updates	Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 .
2026-08-04	Concall / analyst meet	Transcript
2026-08-04	Concall / analyst meet	Transcript
2026-07-30	Concall / analyst meet	Link of Recording
2026-07-29	Change in Management	Change in Management
2026-07-29	General Updates	Grant of 1,20,000 ESOP under JPL ESOP Plan 2022
2026-07-29	Press Release	A press release dated July 29, 2026, titled "Press Release for Unaudited Financial Results for quarter ended June 30, 2026 ".
2026-07-29	Concall / analyst meet	Presentation
2026-07-29	Record Date	Record date for the purpose of Dividend is 04-Sep-2026.
2026-07-29	Board meeting outcome	Jagsonpal Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-22	Concall / analyst meet	Schedule of meet
2026-07-17	Updates	Updates on Acquisition of Aequitas Healthcare Private Limited.
2026-07-15	Updates	Allotment of 94,000 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 ( JPL ESOP 2022 ).
2026-07-08	Updates	Updates on Acquisition of Aequitas Healthcare Private Limited..
2026-07-07	Updates	Updates on Acquisition of Aequitas Healthcare Private Limited.
2026-06-30	Disclosure under SEBI Takeov	Jagsonpal Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of In...
2026-06-29	Press Release	A press release dated Jun 29, 2026, titled "Press Release on Acquisition of Aequitas Healthcare Private Limited. ".

Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.

No short selling reported to NSE in our files.

Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.

Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Jagsonpal Pharmaceuticals Ltd?

Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) has a market capitalisation of Rs 1,552 Cr. at the 2026-10-01 close.

What is the P/E ratio of Jagsonpal Pharmaceuticals Ltd?

Jagsonpal Pharmaceuticals Ltd trades at a P/E of 33.0 on trailing twelve-month profit, at the 2026-10-01 close.

What were Jagsonpal Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Jagsonpal Pharmaceuticals Ltd sales was Rs 82 Cr (+7.9% vs Jun 2025) and net profit was Rs 13 Cr.

What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd?

The 52-week high is Rs 264.50 and the 52-week low is Rs 155.00.